Home Newsfeeds UBS Downgrades Pfizer to Neutral, Lowers Price Target to $47

UBS Downgrades Pfizer to Neutral, Lowers Price Target to $47

UBS analyst Colin Bristow downgrades Pfizer (NYSE:PFE) from Buy to Neutral and lowers the price target from $55 to $47.

byBenzinga Newsdesk

January 26, 2023

1 minute read

UBS analyst Colin Bristow downgrades Pfizer (NYSE:PFE) from Buy to Neutral and lowers the price target from $55 to $47.

Nasdaq Down 0.5%; Lithium Americas Shares Slide

By Avi Kapoor

April 18, 2:54 PM

U.S. stocks traded mostly lower toward the end of trading, with the NASDAQ Composite falling around 0.5% on…

AGBA

3 of 4 Darden Restaurants Analysts See Investors Feasting On Q3 Print

By Priya Nigam

March 24, 10:46 AM

Darden Restaurants, Inc. (NYSE: DRI) Thursday reported an earnings beat for its fiscal third quarter.

DRI

Here’s How Much You Would Have Made Owning Constellation Brands Stock In The Last 15 Years

By Benzinga Insights

July 1, 11:43 AM

Constellation Brands (NYSE:STZ) has outperformed the market over the past 15 years by 10.13% on an annualized basis producing an average annual return of 16.32%. Currently, Constellation Brands has a market capitalization of $42.81 billion.

STZ

News

FangDD Receives Nasdaq Notice Regarding Minimum Bid Price Requirement

By Benzinga Newsdesk

December 14, 9:33 AM

Fangdd Network Group Ltd. (NASDAQ:DUO) ("FangDD" or the "Company") today announced that it has received a written notification from The Nasdaq Stock Market LLC ("Nasdaq") dated December 13, 2023, notifying that the

DUO

UBS Downgrades Pfizer to Neutral, Lowers Price Target to $47

Related Posts

Nasdaq Down 0.5%; Lithium Americas Shares Slide

3 of 4 Darden Restaurants Analysts See Investors Feasting On Q3 Print

Here’s How Much You Would Have Made Owning Constellation Brands Stock In The Last 15 Years

FangDD Receives Nasdaq Notice Regarding Minimum Bid Price Requirement